Description: Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. It is involved in developing TG4050, a therapeutic vaccine that is in phase I clinical trial for the treatment of ovarian cancer, and human papilloma virus (HPV)-negative head and neck cancers; TG4001, a therapeutic vaccine, which is in phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in phase I/IIa clinical trial for the treatment of various solid tumors, such as gastrointestinal adenocarcinoma comprising stomach, pancreas, and colon; and BT-001, an oncolytic virus, which is in phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Sanofi, BioInvent, and Randox. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.
Home Page: www.transgene.fr
400, Boulevard Gonthier d’Andernach
Illkirch-Graffenstaden,
67405
France
Phone:
33 3 88 27 91 00
Officers
| Name | Title |
|---|---|
| Mr. Hedi Ben Brahim | CEO & Director |
| Mr. Jean-Philippe Del | VP & CFO |
| Dr. Eric Quemeneur Ph.D. | Exec. VP & Chief Scientific Officer |
| Ms. Elisabetta Castelli | Director of Investor Relations |
| Mr. John Felitti J.D., LLM | VP, Gen. Counsel & Corp. Sec. |
| Lucie Larguier | Director of Corp. Communications & IR |
| Ms. Gaelle Stadtler | VP & Director of HR |
| Mr. Philippe Slos | Head of Preclinical Regulatory Laboratory |
| Dr. Maud Brandely-Talbot M.D., Ph.D. | VP of Medical Affairs & Chief Medical Officer |
| Mr. Steven H. Bloom R.Ph. | VP & Chief Bus. Officer |
Exchange: PA
Country: FR
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.389 |
| Price-to-Sales TTM: | 10.0691 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 143 |